SciELO - Scientific Electronic Library Online

vol.84 número7Estudios de hipercoagulabilidad en oftalmología: ¿Qué pedir y cuándo?Resultados tensionales tras trabeculectomía a largo plazo: Estudio comparativo entre tipos de glaucoma y tratamiento médico previo índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados



Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google


Archivos de la Sociedad Española de Oftalmología

versión impresa ISSN 0365-6691


RUIZ-MORENO, J.M. et al. Guidelines of clinical practice of the SERV: Treatment of exudative age-related macular degeneration (AMD). Arch Soc Esp Oftalmol [online]. 2009, vol.84, n.7, pp.333-344. ISSN 0365-6691.

Objective: Age related macular degeneration (ARMD) in its neovascular form is a serious disease which produces legal blindness in many patients with poor prognosis if left untreated. We intend to establish a clinical guide with the different therapeutic options that exist nowadays, which may help the ophthalmologists in their clinical practice. Methods: A group of medical retina experts selected by SERV have evaluated the results of different published studies with the drugs currently available, obtaining an evidence-based consensus. Some recommendations have been established for diagnosis, treatment and monitoring of patients with neovascular ARMD. Results: The intravitreal injection of ranibizumab at a dosage of 0.5 mg produces significant improvement of visual acuity in subfoveal lesions, according to data obtained from studies with the highest level of evidence. It should be considered as a first choice drug. The use of bevacizumab, a drug with not approved indication for intraocular use, nor for the treatment of neovascular ARMD can reach a result which is closer to the ones obtained with ranibizumab than to those obtained with photodynamic therapy (PDT) and pegaptanib. The use of intravitreal pegaptanib sodium in intravitreal injection at a dosage of 0.3 mg as a treatment for subfoveal lesions can obtain similar results to the TFD, but with a wider range of injuries. Conclusion: The results of the evidence-based studies are a good guide for the treatment of this disease.

Palabras clave : Age-related Macular Degeneration (AMD); ranibizumab; bevacizumab; pegaptanib; photodynamic therapy; verteporfin; VEGF.

        · resumen en Español     · texto en Español     · Español ( pdf )


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons